← 產業報告目錄
U.S., Europe, and China Myelodysplastic Syndrome (MDS) Treatment Market, By Drug (Lenalidomide, Decitabine, Azacitidine, Luspatercept, Phase 3 Drugs), By Route of Administration (Injection, Oral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (U.S., Europe, China))
出版商 Coherent Market Insights出版日期 2026-07-13頁數 258報告編號 CMR-c2f1184082
授權報價
| Single User Price | $4,500 USD |
| Site License Price | $7,000 USD |
| Enterprisewide Price (Global Site License) | $10,000 USD |
報告摘要
In myelodysplastic syndrome (MDS), some of the blood forming cells in bone marrow become abnormal and have problems in forming new and mature blood cells. The immature blood cells called as blasts get stored in the bone marrow and blood, and obstruct the natural function of the hematological system, which results in depletion of healthy red blood cells, platelets, and white blood cells. It is usually observed in geriatric population and more often in older men compared to women. For instance, according to the American Society of Clinical Oncology (ASCO), age plays an important role in the occurrence of myelodysplastic syndrome, as most of the people diagnosed with the disease are of age 65 and older.
Moreover, increasing possibility of MDS to further progress into rapidly growing cancer of bone marrow cells called acute myeloid leukemia (AML), leads to increasing efforts by key players develop highly effective therapies for MDS treatment. Furthermore, rising awareness about MDS and its symptoms with advanced methods and techniques for early diagnosis and treatment for various forms of the MDS is expected to drive the market growth over the forecast period. Increased understanding of the pathology of the syndrome is directing the research towards developing more specialized and symptom based treatments with effective costs, so that MDS patients can avail these benefits.
Market Dynamics
The increasing prevalence of MDS is expected to drive the demand of drugs used for the treatment of MDS, thereby expected to drive the U.S., Europe, and China myelodysplastic syndrome treatment market growth over the forecast period. Incidence rate for myelodysplastic syndrome has witnessed an increase in the last few years as the average population is ageing every consecutive year. For instance, according to the American Cancer Society report 2018, over 10,000 new cases of MDS occur in the U.S. every year, which is expected to boost the market growth.
Key features of the study
• This report provides in-depth analysis of the U.S., Europe, and China myelodysplastic syndrome (MDS) treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the U.S., Europe, and China myelodysplastic syndrome (MDS) treatment market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and Strategies
• Key companies covered as a part of this study include Bristol Myers Squibb, Otsuka Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd., Mylan N.V., Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Limited, Cipla Limited, Acceleron Pharma, Inc., Onconova Therapeutics, Inc., Aprea Therapeutics, Geron, Fibrogen, Inc., Jazz Pharmaceuticals, AbbVie Inc., Lixte Biotechnology Holdings, Inc., Gilead Sciences, CrystalGenomics, Inc., ALX Oncology Inc., and Keros Therapeutics.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The U.S., Europe, and China myelodysplastic syndrome (MDS) treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the U.S., Europe, and China myelodysplastic syndrome (MDS) treatment market
Market Segmentation
• By Drug (Revenue, USD Bn, 2021-2033)
o Lenalidomide
o Decitabine
o Azacitidine
o Luspatercept
o Phase 3 Drugs
• By Route of Administration (Revenue, USD Bn, 2021-2033)
o Injection
o Oral
• By Distribution Channel (Revenue, USD Bn, 2021-2033)
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
• By Region (Revenue, USD Bn, 2021-2033)
o U.S.
o Europe
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
o China
• Key Players
o Bristol Myers Squibb
o Otsuka Pharmaceutical Co., Ltd.
o Teva Pharmaceutical Industries Ltd.
o Mylan N.V.
o Reddy's Laboratories Ltd.
o Sun Pharmaceutical Industries Limited
o Cipla Limited
o Acceleron Pharma, Inc.
o Onconova Therapeutics, Inc.
o Aprea Therapeutics
o Geron
o Fibrogen, Inc.
o Jazz Pharmaceuticals
o AbbVie Inc.
o Lixte Biotechnology Holdings, Inc.
o Gilead Sciences
o CrystalGenomics, Inc.
o ALX Oncology Inc.
o Keros Therapeutics
目錄 Table of Contents
Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Overview
o Report Description
Market Definition and Scope
o Executive Summary
Market Snapshot, By Drug
Market Snapshot, By Route of Administration
Market Snapshot, By Distribution Channel
Market Snapshot, By Region/Country
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
Drivers
Restraints
Market Opportunities
o Impact Analysis
o Market Trends
o Key Developments
o Disease Type Approval
o Collaboration/Merge/Acquisition
o Regulatory Landscape
o PEST Analysis
o Porter’s Five Forces Analysis
o Epidemiology
o Robust Pipeline Analysis
4. U.S., Europe, and China Myelodysplastic Syndrome (MDS) Treatment Market, By Drug, 2021 – 2033, (USD Billion)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022– 2033
Segment Trends
o Lenalidomide
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
o Decitabine
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
o Azacitidine
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
o Luspatercept
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
o Phase 3 Drugs
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
5. U.S., Europe, and China Myelodysplastic Syndrome (MDS) Treatment Market, By Route of Administration, 2021 – 2033, (USD Billion)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022– 2033
Segment Trends
o Injection
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
o Oral
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
6. U.S., Europe, and China Myelodysplastic Syndrome (MDS) Treatment Market, By Distribution Channel, 2021 – 2033, (USD Billion)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022– 2033
Segment Trends
o Hospital Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
o Retail Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
o Online Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
7. U.S., Europe, and China Myelodysplastic Syndrome (MDS) Treatment Market, By Region/Country, 2021 – 2033, (USD Billion)
o Introduction
Market Share Analysis, By Region/Country, 2026 and 2033 (%)
Y-o-Y Growth Analysis, For Region/Country, 2022–2033
Region/Country Trends
o U.S.
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
o Europe
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
o China
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
8. Competitive Landscape
o Heat Map Analysis
o Market Share Analysis
o Company Profile
Bristol Myers Squibb
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Otsuka Pharmaceutical Co., Ltd.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Teva Pharmaceutical Industries Ltd.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Mylan N.V.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Reddy's Laboratories Ltd.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Sun Pharmaceutical Industries Limited
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Cipla Limited
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Acceleron Pharma, Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Onconova Therapeutics, Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Aprea Therapeutics
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Geron
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Fibrogen, Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Jazz Pharmaceuticals
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
AbbVie Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Lixte Biotechnology Holdings, Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Gilead Sciences
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
CrystalGenomics, Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
ALX Oncology Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Keros Therapeutics
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
o Analyst Views
9. Section
o References
o Research Methodology
o About Us
圖表清單 List of Tables & Figures
NA
NA
提及公司
o Bristol Myers Squibbo Otsuka Pharmaceutical Co.Ltd.o Teva Pharmaceutical Industries Ltd.o Mylan N.V.o Reddy's Laboratories Ltd.o Sun Pharmaceutical Industries Limitedo Cipla Limitedo Acceleron PharmaInc.o Onconova TherapeuticsInc.o Aprea Therapeuticso Gerono FibrogenInc.o Jazz Pharmaceuticalso AbbVie Inc.o Lixte Biotechnology HoldingsInc.o Gilead Scienceso CrystalGenomicsInc.o ALX Oncology Inc.o Keros Therapeutics
量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們